Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „tocilizumab“
Suchtreffer
Begriffe & Kennungen
RoActemra · 4.5 · Concomitant administration of a single dose of 10 mg/kg tocilizumab with 10-25 mg MTX once weekly had no clini
Eintrag öffnenRoActemra · 4.5 · Population pharmacokinetic analyses did not detect any effect of MTX, NSAIDs or corticosteroids on tocilizumab
Eintrag öffnenRoActemra · 4.5 · Population pharmacokinetic analyses did not detect any effect of MTX, NSAIDs or corticosteroids on tocilizumab
Eintrag öffnenRoActemra · 4.5 · When starting or stopping therapy with tocilizumab, patients taking medicinal products which are individually
Eintrag öffnenRoActemra · 4.5 · When starting or stopping therapy with tocilizumab, patients taking medicinal products which are individually
Eintrag öffnenRoActemra · 4.5 · When starting or stopping therapy with tocilizumab, patients taking medicinal products which are individually
Eintrag öffnenRoActemra · 4.8 · 14 Table 2. List of adverse reactions1 identified from the pooled safety-evaluable population from tocilizumab
Eintrag öffnenRoActemra · 4.8 · 18 Neutrophils During routine laboratory monitoring in the tocilizumab all exposure population, a decrease in
Eintrag öffnenRoActemra · 4.8 · 19 Immunogenicity All 112 patients were tested for anti-tocilizumab antibodies at baseline. Two patients devel
Eintrag öffnenRoActemra · 4.8 · 46 Table 1. List of adverse reactions occurring in patients treated with tocilizumab
Eintrag öffnenRoActemra · 4.8 · 48 Hepatic transaminase elevations During routine laboratory monitoring in the tocilizumab 6-month controlled
Eintrag öffnenRoActemra · 4.8 · 49 Injection Site Reactions A total of 28.8 % (15/52) pJIA patients experienced ISRs to tocilizumab subcutaneo
Eintrag öffnenRoActemra · 4.8 · 81 Table 1. List of adverse reactions occurring in patients treated with tocilizumab
Eintrag öffnenRoActemra · 4.8 · 83 anti-tocilizumab antibodies; of these, six (1.4 %) developed neutralising anti-tocilizumab antibodies. Four
Eintrag öffnenRoActemra · 4.8 · 85 Injection site reactions In the tocilizumab subcutaneous weekly group, a total of 6 % (6/100) patients repo
Eintrag öffnenRoActemra · 4.8 · 86 In 6-month controlled clinical trials, the rate of serious infections with tocilizumab 8 mg/kg plus DMARDs
Eintrag öffnenRoActemra · 4.8 · CRS patients The safety of tocilizumab in CRS has been evaluated in a retrospective analysis of data from clin
Eintrag öffnenRoActemra · 4.8 · Clinically significant hypersensitivity reactions associated with tocilizumab and requiring treatment disconti
Eintrag öffnenRoActemra · 4.8 · Description of selected adverse reactions (intravenous use) RA patients The safety of tocilizumab has been stu
Eintrag öffnenRoActemra · 4.8 · Description of selected adverse reactions (intravenous use) RA patients The safety of tocilizumab has been stu
Eintrag öffnen